drugset / Trial / NCT02937571
High Dose Carfilzomib for Newly Diagnosed Myeloma
Phase 1/2
Completed
29 enrolled
Memorial Sloan Kettering Cancer Center
Celgene Corporation · collabOnyx/Amgen · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test whether giving high doses of carfilzomib along with the other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by patients. In addition, the study is designed to test the amount of remaining myeloma cells in the body after treatment with higher carfilzomib doses which is known as minimal residual disease (MRD).
Timeline
- Start
- 2016-10
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 45 mg/m2 | — |
| Subject | Carfilzomib | Other / unclassified | 56 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |